PsychoGenics Announces Drug Discovery Agreement with Cephalon.
PsychoGenics Inc. announced that it has entered into a drug discovery agreement with Cephalon Inc. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies. PsychoGenics and Cephalon aim to jointly identify drug candidates suitable for clinical development. If Cephalon undertakes further development of the clinical candidates PsychoGenics, will receive milestone payments, as well as royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.
